EGFR and central nervous system neoplasm: Other molecular characteristics of scGBM, including TERT promoter mutations, EGFR amplification, or combined gain of chromosome 7 and loss of chromosome 10 (+7/−10) mentioned in the 2021 WHO Classification of CNS Tumors, were not possible to examine [8].